An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia

Robert Adam; Miriam Priglinger; Timothy Harrington; David Gottlieb; Martin Krause

doi:10.1016/j.jstrokecerebrovasdis.2013.12.013

An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):e373-4. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.013. Epub 2014 Feb 28.

Authors

Robert Adam¹, Miriam Priglinger², Timothy Harrington³, David Gottlieb⁴, Martin Krause⁵

Affiliations

¹ Department of Neurology, Royal North Shore Hospital, Sydney, Australia; Department of Medicine, University of Sydney, Sydney, Australia. Electronic address: robert.adam@sydney.edu.au.
² Department of Neurology, Royal North Shore Hospital, Sydney, Australia.
³ Department of Radiology, Royal North Shore Hospital, Sydney, Australia.
⁴ Department of Medicine, University of Sydney, Sydney, Australia.
⁵ Department of Neurology, Royal North Shore Hospital, Sydney, Australia; Department of Medicine, University of Sydney, Sydney, Australia.

PMID: 24582788
DOI: 10.1016/j.jstrokecerebrovasdis.2013.12.013

Abstract

Essential thrombocythemia (ET) is a risk factor for ischemic stroke and, far more rarely, hemorrhage. We report the case of an untreated 32-year-old woman with a history of JAK2 V617F-positive ET with cerebellar and subarachnoid hemorrhages without evidence of sinus vein thrombosis. She was commenced on oral cytotoxic and antiplatelet therapy. This case report discusses the underlying mechanism of hemorrhagic thrombocythemia and the management dilemma presented by the recommended treatment implications.

Keywords: Hemorrhagic stroke; acquired von Willebrand disease; antiplatelet; essential thrombocythaemia; myeloproliferative disorder; young stroke.

Publication types

Case Reports

MeSH terms

Adult
Aspirin / therapeutic use
Cerebral Angiography / methods
Female
Genetic Predisposition to Disease
Humans
Hydroxyurea / therapeutic use
Intracranial Hemorrhages / diagnosis
Intracranial Hemorrhages / drug therapy
Intracranial Hemorrhages / etiology*
Janus Kinase 2 / genetics
Magnetic Resonance Imaging
Mutation
Platelet Aggregation Inhibitors / therapeutic use
Risk Factors
Subarachnoid Hemorrhage / diagnosis
Subarachnoid Hemorrhage / drug therapy
Subarachnoid Hemorrhage / etiology
Thrombocythemia, Essential / complications*
Thrombocythemia, Essential / diagnosis
Thrombocythemia, Essential / drug therapy
Thrombocythemia, Essential / genetics
Tomography, X-Ray Computed
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
JAK2 protein, human
Janus Kinase 2
Aspirin
Hydroxyurea